| abstract |
The invention is directed to physiologically active compounds of general formula (I), wherein R1 is hydrogen, halogen, lower alkyl or lower alkoxy; X?1, X2 and X6¿ independently represent N or CR2; and one of X?3, X4 and X5¿ represents CR3 and the others independently represents N or CR2 [where R2 is hydrogen, halogen, lower alkyl or lower alkoxy; and R3 represents a group -L1-(CH2)n-C(=O)-N(R4)-CH2-CH2-Y]; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4(α4β1). |